Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: A bivariate meta-analysis

Internal Medicine

Volumn 50, Issue 22, 2011, Pages 2783-2791

  Lu, Yuan ^a   Chen, Yi Qiang ^a   Guo, Ya Ling ^a   Qin, Shou Ming ^a   Wu, Cong ^a   Wang, Ke ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

D glucan; Diagnosis; Invasive fungal disease

Indexed keywords

BETA 1,3 GLUCAN; GALACTOMANNAN;

ARTICLE; ASPERGILLOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; META ANALYSIS; NEGATIVE LIKELHOOD RATIO; POSITIVE LIKELHOOD RATIO; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ASPERGILLOSIS; BETA-GLUCANS; BIOLOGICAL MARKERS; CANDIDIASIS, INVASIVE; HUMANS; LIKELIHOOD FUNCTIONS; LINEAR MODELS; MANNANS; MYCOSES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 81155139246     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.6175     Document Type: Article

References (37)

1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 366: 1013-1025, 2005.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317, 2004.
3. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91: 986-989, 2006.
4. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant- Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50: 1101-1111, 2010.
5. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant- Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50: 1091-1100, 2010.
6. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 59: 407-414, 2007.
7. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821, 2008.
8. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. {beta}-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis. Clin Infect Dis 52: 750-770, 2011.
9. Ascioglu S, Rex JH, de PB, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34: 7-14, 2002.
10. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med 149: 889-897, 2008.
11. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326: 41-44, 2003.
12. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 25, 2003.
13. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271: 703-707, 1994.
14. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58: 982-990, 2005.
15. Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 323: 157-162, 2001.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 21: 1539-1558, 2002.
17. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21: 1525-1537, 2002.
18. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58: 882-893, 2005.
19. Dwamena Ben A. Midas. A program for Meta-analytical Integration of Diagnostic Accuracy Studies in Stata. Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan 2007.
20. Acosta J, Catalan M, Del Palacio-Perez-Medel A, et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1--> 3) -beta-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect 17: 1053-1060, 2011.
21. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 48: 4083-4088, 2010.
22. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Preemptive treatment of fungal infection based on plasma (1 --> 3)beta-D-glucan levels after liver transplantation. Infection 35: 346-351, 2007.
23. Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57: 287-295, 2008.
24. Hirata Y, Yokote T, Kobayashi K, et al. Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies. Leuk Lymphoma 51: 853-859, 2010.
25. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47: 129-133, 2009.
26. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42: 2733-2741, 2004.
27. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 49: 1650-1659, 2009.
28. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37: 1624-1633, 2009.
29. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis 46: 1864-1870, 2008.
30. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff de velopment, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39: 199-205, 2004.
31. Pazos C, Ponton J, Del PA. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43: 299-305, 2005.
32. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46: 1009-1013, 2008.
33. Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-Dglucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 85: 745-752, 2000.
34. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46: 878-885, 2008.
35. Yoshida K, Shoji H, Takuma T, Niki Y. Clinical viability of Fungitell, a new (1-->3)-beta-D: -glucan measurement kit, for diagnosis of invasive fungal infection, and comparison with other kits available in Japan. J Infect Chemother 17: 473-477, 2011.
36. Metan G, Agkus C, Buldu H, Koc AN. The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections. Infection 38: 217-221, 2010.
37. Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1- >3) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 54: 4879-4886, 2010.